本期刊·见为诸位介绍一份眼科学领域期刊—Ocular Immunology and Inflammation。除了对期刊进行详尽的介绍外，还向您介绍刊内近三年高被引文章，以及近一年高阅读量文章：

• 法利昔单抗玻璃体内注射后葡萄膜炎1例报告

• 眼瘢痕性类天疱疮眼表疾病的治疗

• 中期葡萄膜炎的流行病学研究

Print ISSN: 0927-3948 Online ISSN: 1744-5078

期刊官方网站：https://www.tandfonline.com/journals/ioii20

Ocular Immunology and Inflammation采取双月刊形式，致力于成为全球范围内眼部炎症反应及其免疫调控机制相关基础与临床研究的国际出版平台。期刊关注的主题较为广泛，包括眼部炎症基础机制的最新科研进展，以及针对葡萄膜炎、角膜炎、视网膜炎和视神经炎等疾病的诊断技术与治疗策略的新颖见解。

该期刊已被SCIE, Scopus, MEDLINE等国际知名数据库收录。

影响因子

根据JCR显示，Ocular Immunology and Inflammation

• 在眼科学领域排名44/98

CiteScore

根据Scopus显示, Ocular Immunology and Inflammation

2024年CiteScore为4.6

2024年CiteScore Tracker为3.3

• 在医学：眼科学领域排名31/141

• 在医学：免疫学和变态反应领域排名123/231

中国科学院分区

根据2025年发布的中国科学院期刊分区表（升级版）显示：

• 大类及分区：医学4区

• 小类及分区：眼科学3区

作者须知

接收文章类型

Ocular Immunology and Inflammation 期刊接受原创研究论文、临床病例报告、评论、致编辑信件、会议摘要和受邀社论。

审稿周期

• 从提交稿件到获取初审意见，平均需要12天

• 获取首个同行评审决定，平均需要44天

• 稿件一旦接受后，在线出版平均需要11天

文章出版费（APC）

请访问期刊主页或Taylor & Francis Open Access APC Cost Finder查找适用于作者所在国家及不同文章类型的费用情况。若您所在的机构或相关资助者与我们签有开放获取出版协议，您可能有资格获得APC支持，请访问我们的作者服务网站以了解更多！

Taylor & Francis现在开通APC便捷支付功能，可以一键通过微信、支付宝和银联使用人民币便捷付款。

编辑团队

Ocular Immunology and Inflammation期刊的主编由美国最大的眼科研究所之一威尔默眼科研究所的Jennifer E. Thorne博士和土耳其Bayrampasa 眼科医院的Ilknur Tugal-Tutkun博士共同担任。

该期刊的编辑委员会汇聚了全球各地的精英学者，成员包括来自美国、印度、日本、新加坡、意大利等多个国家的杰出研究人员。尤为值得一提的是，中国编委团队中吸纳了国际知名的葡萄膜炎专家——重庆医科大学的杨培增教授，他的加入无疑为期刊增添了更为丰富的专业视角与深度。

主编介绍

Jennifer E. Thorne

Jennifer E. Thorne博士是约翰霍普金斯大学医学院教授，同时任职于美国威尔默眼科研究所。作为葡萄膜炎及免疫介导性眼病领域的国际权威专家，她的临床专长涵盖各类复杂眼内炎症性疾病的评估与治疗。Thorne博士的研究聚焦三大方向：白点综合征（包括鸟枪弹样脉络膜视网膜病变、多灶性脉络膜炎和点状内层脉络膜病变）、青少年特发性关节炎相关葡萄膜炎的系统管理，以及免疫抑制疗法在眼炎症性疾病中的临床应用与疗效评估。

Ilknur Tugal-Tutkun

Ilknur Tugal-Tutkun博士任职于土耳其Bayrampasa 眼科医院，其研究方向：葡萄膜炎和眼部免疫学。

中国编委

杨培增

杨培增，重庆医科大学第一临床学院教授、博士生导师，国际著名葡萄膜炎专家，被业界誉为“中国葡萄膜炎诊治第一人”。研究方向：葡萄膜炎等常见致盲眼病的发生机制及防治研究。

作者分布

根据JCR显示，近三年在Ocular Immunology and Inflammation发文的国家中，发文前三的国家/地区有：

• 美国

• 印度

• 中国

近三年，在Ocular Immunology and Inflammation发文的全球高校和科研机构中，发文数量排名前三位的是：

• 伦敦大学

• 克利夫兰诊所基金会

• 加州大学系统

近三年内高被引文章

法利昔单抗玻璃体内注射后葡萄膜炎1例报告

作者：Filomena Palmieri et al.

文章摘要：

Purpose

Faricimab, a novel pharmaceutical agent targeting both angiopoietin-2 and vascular endothelial growth factor-A pathways, has gained approval for treating neovascular age-related macular degeneration and diabetic macular oedema. While clinical trials have demonstrated its favorable safety profile, this research presents two cases of hypertensive uveitis following intravitreal Faricimab injections.

Methods

Medical history, clinical findings and multimodal images were retrospectively collected.

Results

The patients experienced elevated intraocular pressure, mutton-fat keratic precipitates, anterior and posterior segment inflammation shortly after faricimab administration.

Conclusions

These cases prompt further investigation into the potential risk of uveitis associated with faricimab and underscore the importance of continued monitoring and research to elucidate its real-world safety profile.

近一年内高阅读量文章

眼瘢痕性类天疱疮眼表疾病的治疗

作者： Kaleb S. Abbott et al.

文章摘要：

Purpose

While substantial research has focused on systemic immunomodulatory therapy for ocular cicatricial pemphigoid (OCP), limited data exist on managing associated ocular surface disease (OSD). This study evaluates treatments for OCP-related OSD at our institution.

Methods

We conducted a retrospective analysis of patients diagnosed with cicatrizing conjunctivitis at the University of Colorado Hospital from January 1, 2013, to October 31, 2023. Patients with cicatrizing conjunctivitis due to non-OCP conditions were excluded, and disease severity was classified using the Foster Staging System.

Results

Our review included 30 patients with OCP, all with at least six months of follow-up. The mean age of symptom onset (n = 19) was 62.2 years (SD = 16.4), while the mean age at diagnosis (n = 28) was 65.1 years (SD = 12.7). The most common OSD treatments at the last visit were preservative-free artificial tears (87%), topical corticosteroids (43%), autologous serum eye drops (40%), topical antibiotics (30%), and topical immunomodulators (23%). All patients used at least one treatment, with 83.3% on prescription therapies. Patients averaged 3.33 (SD: 1.4) treatments, with 1.7 (SD: 1.2) being prescriptions. Topical immunomodulators had the highest discontinuation rate at 73.1% (n = 19/26). Autologous serum eye drops and topical corticosteroids were the least discontinued treatments. Number of total treatments, prescriptions, and procedures sharply increased at stage three OCP.

Conclusions

The number of treatments and procedures increased with OCP severity, indicating that advanced OCP often necessitated more intensive OSD management.

中期葡萄膜炎的流行病学研究

作者： Sonya Besagar et al.

文章摘要：

Intermediate uveitis is defined as inflammation of the vitreous and pars planitis. Etiology can be infectious, associated with a systemic disease, neoplastic or idiopathic. Pars planitis is the term used for idiopathic intermediate uveitis that presents with snowballs and snowbanks. While relatively rare, intermediate uveitis is present globally and typically affects adult females. Awareness of the presentation and a dilated fundus examination in patients presenting with floaters is essential to the diagnosis. PCR testing has enhanced the ability to diagnose infectious and neoplastic conditions that masquerade as intermediate uveitis. A structured review of systems and focused imaging, and laboratory testing will assist with early diagnosis and initiation of treatment.

"Jour - Know"

为帮助更多科研人员选择更加合适的期刊，Taylor & Francis推出专栏——刊·见，该专栏致力于为读者和广大科研人员带来Taylor & Francis旗下期刊的详细解读，从期刊的基本情况、编委阵容、社会影响力到审稿速度、高被引文章等实用信息，专栏将为您带来最详细的介绍，让您更加全面地了解Taylor & Francis旗下优秀的国际期刊，帮助更多中国卓越科研成果顺利在国际期刊上发表。